Abstract
Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
CNS & Neurological Disorders - Drug Targets
Title: Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
Volume: 9 Issue: 6
Author(s): Nahuai Badiola, Marc Suarez-Calvet and Alberto Lleo
Affiliation:
Keywords: Tau, tauopathies, Alzheimer, frontotemporal dementia, kinase inhibitors, dementia, immunization, Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, corticobasal syndrome, frontotemporal lobar degeneration, FTLD, post-encephalitic parkinsonism, Down syndrome, chronic traumatic encephalopathy, Niemann-Pick disease type C, postencephalitic parkinsonism, phosphorylation, glycation, glycosylation, ubiquitination, sumoylation, polyamination, nitration, nitrosylation, truncation, multiphoton microscopy, alsterpaullone, SB216763, tau fibrillization, phenothiazines, porphyrins, polyphenols, anthraquinones, phenyl thiazolylhydrazide benzofuran, pyrimidotriazines, quinoxaline, aminothienopyridazines, chloroquine, NAPVSIPQ, SMaRT technology, MMSE, AZD1080
Abstract: Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubuleassociated protein tau in the central nervous system. In these disorders, tau is believed to cause neurodegeneration and neuronal loss due to the loss of function of the normal protein, and/or the gain of toxic properties by generating multimeric species. The obstacles found in amyloid-based therapies in Alzheimers disease, the most common tauopathy, have stimulated the search for alternative targets, including tau. In this article, we review the strategies aimed at reducing tau phosphorylation and aggregation as a target for drug intervention in tauopathies.
Export Options
About this article
Cite this article as:
Badiola Nahuai, Suarez-Calvet Marc and Lleo Alberto, Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237403
DOI https://dx.doi.org/10.2174/187152710793237403 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Dehydroepiandrosterone (DHEA) and its Sulphate (DHEAS) in Alzheimer’s Disease
Current Alzheimer Research Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Membrane Damage Induced by Amyloid Beta and a Potential Link with Neuroinflammation
Current Pharmaceutical Design Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis Childhood and Adulthood Rural Residence Increases the Risk of Dementia: NEDICES Study
Current Alzheimer Research Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Hypopituitarism in the Elderly: Multifaceted Clinical and Biochemical Presentation
Current Aging Science Biochemical and Therapeutic Effects of Antioxidants in the Treatment of Alzheimers Disease, Parkinsons Disease, and Amyotrophic Lateral Sclerosis
Current Drug Targets - CNS & Neurological Disorders Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Current Alzheimer Research